Euroconference on tissue repair and ulcer/wound healing: molecular mechanisms, therapeutic targets and future directions

Bibliography

• BLESCH A, CONNER JM, TUSZYNSKI MH: Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther. (2001) 8:954–960.
   PubMed Web of Science ®Google Scholar
• BLESCH A, UY HS, DIERGARDT N, TUSZYNSKI MH: Neurite outgrowth can be modulated in vitro using a tetracycline-repressible gene therapy vector expressing human nerve growth factor. J. Neurosci. Res. (2000) 59:402–409.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI MH: Intraparenchymal NGF infusions rescue degenerating cholinergic neurons. Cell Transplant. (2000) 9:629–636.
   PubMed Web of Science ®Google Scholar
• BOWES M, TUSZYNSKI MH, CONNER J, ZIVIN JA: Continuous intrathecal fluid infusions elevate nerve growth factor levels and prevent functional deficits after spinal cord ischemia. Broth Res. (2000) 883:178–183.
   PubMed Web of Science ®Google Scholar
• SZABO IL, PAT R, SOREGHAN B et al.: NSAIDs inhibit the activation of egr- I gene in microvascular endothelial cells. A key to inhibition of angiogenesis? Physiol Paris (2001) 95(1-6):379–383.
   Google Scholar
• •A discussion of the non-steroidal anti-inflammatory drug class of drugs modulating the expression of this master regulator of gene transcription.
   Google Scholar
• TUSZYNSKI MH, GRILL R, JONES LL, McKAY HM, BLESCH A: Spontaneous and augmented growth of axons in the primate spinal cord: effects of local injury and nerve growth factor-secreting cell grafts. J. Comp. Neurol (2002) 449:88–101.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI MH, SMITH DE, ROBERTS J, McKAY H, MUFSON E: Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate 0-amyloid plaque deposition. Exp. Neurol (1998) 154:573–582.
   PubMed Web of Science ®Google Scholar
• KIM W-H, MASUMOTO K, BESSHO K, NAKAMURA T: Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver fiobrosis. Am. J. Path. (2005) 166:1017–1028.
   PubMed Web of Science ®Google Scholar
• •A link between an anabolic growth factor and the resolution of tissue destruction.
   Google Scholar
• MIZUNO S, MATSUMOTO K, LI M-Y, NAKUMURA T: HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. (2005) 19:580–583.
   PubMed Web of Science ®Google Scholar
• MATSUNO Y, IWATA H, UMEDA Y et al.: Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis. Gene Ther. (2003) 10:1559–1566.
   PubMed Web of Science ®Google Scholar
• OE H, KAIDO T, FURUYAMA H, MORI A, IMAMURA M: Simulataneous transfer of vascular endothelial growth factor and hepatocyte growth factor genes effectively promotes liver regeneration after hepatectomy in cirrhotic rats. Hepatogastroenterology (2004) 51:1641–1647.
   PubMed Web of Science ®Google Scholar
• ••Roles for multiple growth factors in promoting tissue repair in the liver.
   Google Scholar
• XUE F, TAKAHARA T, YATA Y et al: Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy. Gut (2003)52:694–700.
   PubMed Web of Science ®Google Scholar
• SHIMAMARA M, SATO N, OSHIMA K et al.: Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischaemic injury without cerebral oedema in rat model. Circ. (2004) 109:424–431.
   PubMed Web of Science ®Google Scholar
• ••Hepatocyte growth factor promotes tissuerepair in the brain. A pleiotropic anabolic growth factor.
   Google Scholar
• MATSUKI A, YAMAMOTO S, NAKAGAMI H et al.: No influence of tumour growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem. Biophy. Res. Commun. (2004) 315:59–64.
   PubMed Web of Science ®Google Scholar
• HASHIYA N, JO N, AOKI M et a/.: In vivo evidence of angiogenesis induced by transcription factor ets-1: ets-1 is located upstream of angiogenesis cascade. Circulation (2004) 109:3035–3041.
   Google Scholar
• ONO I, YAMASHITA T, HIDA T et al: Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J. Surg. Res. (2004) 120:47–55.
   PubMed Web of Science ®Google Scholar
• ONO I, YAMASHITA T, HIDA T et al: Combined administration of basic fibroblast growth factor protein and the hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. Wound Rep. Regen. (2004) 12:67–79.
   PubMed Web of Science ®Google Scholar
• MORISHITA, R, AOKI M, HASHIYA, N et al: Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr. Gene Ther. (2004) 4:199–206.
   PubMed Web of Science ®Google Scholar
• MAKINO H, OGIHARA, T, MORISHITA R: Gene therapy for arterial 747 Expert Op/n. Investig. Drugs (2005) 14(6) diseases. Nippon Rinsho lap. I Clin. Med. (2005) 63:491–497.
   Google Scholar
• MORISHITA R, AOKI M, HASHIYA N et al.: Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension (2004) 44:203–209.
   PubMed Web of Science ®Google Scholar
• CHAT J, BAATAR D, TARNAWSKI AS: Serum response factor promotes re-epithelialisation and muscular structure restoration during gastric ulcer healing. Gastroenterol (2004) 126:1809–1818.
   PubMed Web of Science ®Google Scholar
• ••Gene therapy with a transcription factor 1:can this be applied safely to human studies?
   Google Scholar
• CHAT J, BAATAR D, MOON W, TARNAWSKI AS: Expression of serum response factor in normal rat gastric mucosa. J. Physiol Pharmacol (2002) 53:289–294.
   PubMed Web of Science ®Google Scholar
• CHAT J, JONES MK, TARNAWSKI AS: Serum response factor is a critical requirement for VEGF signalling in endothelial cells and VEGF-induced angiogenesis. FASEB J. (2004) 18:1264–1266.
   PubMedGoogle Scholar
• HOUSTON P, WHITE BP, CAMPBELL CJ, BRADDOCK M: Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. Human Gene Ther. (1999) 10:3031–3044.
   PubMed Web of Science ®Google Scholar
• SZABO IL, PAT R, SOREGHAN B et al: NSAIDs inhibit the activation of egr-1 in microvascular endothelial cells. A key to inhibition of angiogenesis? Physiol Paris 95 (2000:379–383.
   Google Scholar
• BRYANT M, DREW GM, HOUSTON P et al.: Tissue repair with a therapeutic transcription factor. Human Gene Ther. (2000) 11:2143–2158.
   PubMed Web of Science ®Google Scholar
• ••Gene therapy with a transcription factor 2: can this be applied safely to human studies?
   Google Scholar
• HOUSTON P, CAMPBELL CJ, SVAREN J, MILBRANDT J, BRADDOCK M: The transcriptional corepressor NAB2 blocks egr-1 mediated growth factor activation and angiogenesis. Biochem. Biophys. Res. Comm. (2001) 283:480–486.
   PubMed Web of Science ®Google Scholar
• BRADDOCK M, CAMPBELL CJ, HOUSTON P. Therapeutic applications of the transcriptional co-repressor proteins NAB1 and NAB2 in regenerative medicine. 'Drugs (2000) 3:783–787.
   Google Scholar
• BRADDOCK M: Wound repair in skin and bone. Science Med. (2002) 8:218–229.
   Google Scholar
• BRADDOCK M, HOUSTON P, CAMPBELL CJ, ASHCROFT P: Born again bone: tissue engineering for bone repair. News Physiol ScL (2001) 16:208–213.
   PubMedGoogle Scholar
• BRADDOCK M, QUINN AJ: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nature Rev Drug. Disc. (2004) 3:330–339
   PubMed Web of Science ®Google Scholar
• VINCENTI MP, BRINCKERHOFF CE: Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-113. Arthritis Res. (2001) 3:381–388.
   PubMedGoogle Scholar
• BRZOZOWSKI T, KONTUREK PC, KONTUREK SJ et al.: Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regul Peptides (2004) 120:39–51.
   PubMed Web of Science ®Google Scholar
• TALBOT C, SAGAR PM, JOHNSTON MJ, FINAN PJ, BURKE D: Infliximab in the surgical management of complex fistulating and Crohn's disease. Colorectal Dis. (2005) 7:164–168.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, WAGNER CL, BALA M et al: Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol Hepatol (2004) 2:542–553.
   PubMed Web of Science ®Google Scholar
• SANDS BE, ANDERSON FH, BERNSTEIN CN et al: Infliximab maintenance therapy for fistulizing Crohn's disease. New Engl. Med. (2004) 350:876–885.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al: ACCENT I study group: maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER S, LOFTUS JR EV et al: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol (2004) 99:1984–1989.
   PubMed Web of Science ®Google Scholar
• •Switching TNF therapy in Crohn's disease has efficacy.
   Google Scholar
• SANDBORN WJ. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disorders. (2004) 4:S25–S33.
   PubMedGoogle Scholar
• HAWES RH: Best of DDW 2004. Rev Gastroenterol Disorders (2004) 4:129–161.
   Google Scholar
• BOURNE PC, TERZYAN SS, CLOUD G et al.: Three-dimensional structures of a humanized anti-IFN-y Fab (HuZAF) in two crystal forms. Acta Cryst. (2004) D60:1761-1769.
   Google Scholar
• CARPENTER PA, APPELBAUM FR, COREY L et al: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99:2712–2719.
   PubMed Web of Science ®Google Scholar
• CARPENTER PA, SANDERS JE: Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr. Transplant. (2003) 7\(Suppl. 3):19–31.
   Google Scholar
• TRAJKOVIC V: Nuvion. Protein Design Labs. Curr. Opin. Invest. Drugs (2002) 3:411–414.
   PubMedGoogle Scholar
• GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. New Engl. I Med. (2003) 348:24–32.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, ROTGEERTS P: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I: immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. Physiol Gastrointest. Liver Physiol (2005) 288:G169–G174.
   Google Scholar
• LINDENBOOM K, BRAZIER G: Millenium Pharmaceuticals announces Phase II data for MLN-02 in Crohn's disease. Press release, Millenium Pharmaceuticals, MA, USA (September 2002).
   Google Scholar
• VIATEAU V, GUILLEMIN G, YANG YC et al.: A technique for creating critical-size defects in the metatarsus of sheep for use in investigation of healing of long-bone defects. Am. I Vet. Res. (2004) 65:1653–1657.
   PubMed Web of Science ®Google Scholar
• KONTUREK PC, BRZOZOWSKI T, KANIA J et al: Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat. Scand. I Gastroenterol (2003) 5:468–476.
   Web of Science ®Google Scholar
• KONTUREK PC, BRZOZOWSKI T, KANIA J et al: Pioglitazone, a specific ligand of peroxisome prolferator-activated receptor-y, accelerates gastric ulcer healing in rat. Eur. I Pharmacol (2003) 472:213–220.
   PubMed Web of Science ®Google Scholar
• ••A non-putative PPAR response element- dependent mechanism for a PPAR-y agonist in ulcer healing. A possible mechanism to identify new targets controlling gastric tissue repair.
   Google Scholar
• BRZOZOWSKA I, TARGOSZ A, SLIWOWSKI Z et al.: Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (I\10)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J. Physiol. Pharmacol. (2004) 55:773–790.
   PubMed Web of Science ®Google Scholar
• http://www.ceregene.com Information regarding CERE-110 (NeuroRescue AD) an AAV expressing NGF for the treatement of Alzheimer's disease.
   Google Scholar
• http://www.IBDTrials.com Source of information on current clinical trials in inflammatory bowel disease sponsored by Protein Design Labs (PDL).
   Google Scholar
• http://www.pdl.com PDL website. Source of information on the protein products in clinical trials for IBD, asthma, multiple sclerosis and oncology that are sponsored by PDL.
   Google Scholar
• http://www.genzyme.com Source of information on the status of clinical trials with HIF-1 a.
   Google Scholar